Publikationen

2018

  • de Koning HJ, Gulati R, Moss SM, Hugosson J, Pinsky PF, Berg CD, Auvinen A, Andriole GL, Roobol MJ, Crawford ED, Nelen V, Kwiatkowski M, Zappa M, Luján M, Villers A, de Carvalho TM, Feuer EJ, Tsodikov A, Mariotto AB, Heijnsdijk EAM, Etzioni R. The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials. Cancer. 124(6):1197-206; 2018
  • Wetterauer Ch, Ebbing J, Seifert HH, Kwiatkowski M, Wyler SF, Recker F. Gedanken zur Optimierung der Prostatakrebsvorsorge. Info Onkologie & Hämatologie. (6):11-13; 2018
  • Wetterauer Ch, Kwiatkowski M. Screening mit Augenmass. Info Onkologie & Hämatologie. (6):1; 2018

2017

  • Tsodikov A, Gulati R, Heijnsdijk EAM, Pinsky PF, Moss SM, Qiu S, de Carvalho TM, Hugosson J, Berg CD, Auvinen A, Andriole GL, Roobol MJ, Crawford ED, Nelen V, Kwiatkowski M, Zappa M, Luján M, Villers A, Feuer EJ, de Koning HJ, Mariotto AB, Etzioni R. Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials. Ann Intern Med. 167(7):449-455; 2017
  • Walter SD, de Koning HJ, Hugosson J, Talala K, Roobol MJ, Carlsson S, Zappa M, Nelen V, Kwiatkowski M, Páez Á, Moss S, Auvinen A. ERSPC Cause of Death Committees. Impact of cause of death adjudication on the results of the European prostate cancer screening trial. Br J Cancer. 116(1):141-148; 2017
  • Briollais L, Ozcelik H, Xu J, Kwiatkowski M, Lalonde E, Sendorek DH, Fleshner NE, Recker F, Kuk C, Olkhov-Mitsel E, Savas S, Hanna S, Juvet T, Hunter GA, Friedlander M, Li H, Chadwick K, Prassas I, Soosaipillai A, Randazzo M, Trachtenberg J, Toi A, Shiah Y, Fraser M, van der Kwast T, Bristow RG, Bapat B, Diamandis EP, Boutros PC, Zlotta AR. Germline mutations in the Kallikrein 6 region and predisposition for aggressive prostate cancer. J Natl Cancer Inst. 109(4):258-265; 2017
  • Kwiatkowski M, Wyler SF, Recker F, Huber A, Grobholz R. Auf dem Weg zum individuellen, risikoadaptierten PSA-Screening. Die Kontroverse um zwei Studien – die keine mehr ist. Pipette (6):15-17; 2017

2016

  • Randazzo M, Muller A, Carlsson S, Eberli D, Huber A, Grobholz R, Manka L, Mortezavi A, Sulser T, Recker F, Kwiatkowski M. A positive family history as a risk factor for prostate cancer in a population-based study with organised prostate-specific antigen screening: results of the Swiss European Randomised Study of Screening for Prostate Cancer (ERSPC, Aarau). BJU Int. 117(4):576-83; 2016
  • Carlsson SV, de Carvalho TM, Roobol MJ, Hugosson J, Auvinen A, Kwiatkowski M, Villers A, Zappa M, Nelen V, Páez A, Eastham JA, Lilja H, de Koning HJ, Vickers AJ, Heijnsdijk EA. Estimating the harms and benefits of prostate cancer screening as used in common practice versus recommended good practice: A microsimulation screening analysis. Cancer. 2016 Jul 26. doi: 10.1002/cncr.30192. [Epub ahead of print]
  • Bokhorst LP, Zappa M, Carlsson SV, Kwiatkowski M, Denis L, Paez A, Hugosson J, Moss S, Auvinen A, Roobol MJ. Correlation between stage shift and differences in mortality in the European Randomized study of Screening for Prostate Cancer (ERSPC). BJU Int. 2016 Apr 22. doi: 10.1111/bju.13505. [Epub ahead of print]
  • Schiffmann J, Grindei M, Tian Z, Yassin DJ, Steinwender T, Leyh-Bannurah SR, Randazzo M, Kwiatkowski M, Karakiewicz PI, Hammerer P, Manka L. Limitations of Elastography Based Prostate Biopsy. J Urol. 195(6):1731-6; 2016
  • Auvinen A, Moss SM, Tammela TL, Taari K, Roobol MJ, Schroder FH, Bangma CH, Carlsson S, Aus G, Zappa M, Puliti D, Denis LJ, Nelen V, Kwiatkowski M, Randazzo M, Paez A, Lujan M, Hugosson J. Absolute Effect of Prostate Cancer Screening: Balance of Benefits and Harms by Center within the European Randomized Study of Prostate Cancer Screening. Clin Cancer Res 22(1):243-9; 2016
  • Prause L, Kwiatkowski M, Recker F. Individuelles,  risikoadaptiertes PSA-Screening. Eine Standortbestimmung. Info@onkologie (4):20-22; 2016

2015

  • Randazzo M, Beatrice J, Huber A, Grobholz R, Manka L, Chun FK, Recker F, Kwiatkowski M. A "PSA Pyramid" for Men with Initial Prostate-specific Antigen ≤3 ng/ml: A Plea for Individualized Prostate Cancer Screening. Eur Urol. 68(4):591-7; 2015
  • Randazzo M, Beatrice J, Huber A, Grobholz R, Manka L, Wyler SF, Chun FF, Recker F, Kwiatkowski M. Influence of metformin use on PSA values, free-to-total PSA, prostate cancer incidence and grade and overall survival in a prospective screening trial (ERSPC Aarau). World J Urol 33(8):1189-96; 2015
  • Randazzo M, Beatrice J, Huber A, Grobholz R, Manka L, Chun FK, Kluth LA, Wyler SF, Recker F, Kwiatkowski M. Is further screening of men with baseline PSA < 1 ng ml(-1) worthwhile? The discussion continues-Results of the Swiss ERSPC (Aarau). International journal of cancer. 137(3):553-9; 2015
  • Randazzo M, Beatrice J, Huber A, Grobholz R, Manka L, Recker F, Kwiatkowski M. Differences among men on active surveillance for very low-risk prostate cancer detected through population-based versus opportunistic prostate-specific antigen-screening. Urol. Int. 94(3):330-6; 2015
  • Kwiatkowski M, Randazzo M, Kluth L, Manka L, Huber A, Recker F. Prostate cancer screening: and yet it moves! Asian journal of andrology. 17(3):437-8; 2015.
  • Buzzoni C, Auvinen A, Roobol MJ, Carlsson S, Moss SM, Puliti D, de Koning HJ, Bangma CH, Denis LJ, Kwiatkowski M, Lujan M, Nelen V, Paez A, Randazzo M, Rebillard X, Tammela TL, Villers A, Hugosson J, Schroder FH, Zappa M. Metastatic Prostate Cancer Incidence and Prostate-specific Antigen Testing: New Insights from the European Randomized Study of Screening for Prostate Cancer. Eur Urol. 68(5):885-90; 2015
  • Heijnsdijk EA, de Carvalho TM, Auvinen A, Zappa M, Nelen V, Kwiatkowski M, Villers A, Paez A, Moss SM, Tammela TL, Recker F, Denis L, Carlsson SV, Wever EM, Bangma CH, Schroder FH, Roobol MJ, Hugosson J, de Koning HJ. Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data. Journal of the National Cancer Institute. 107(1):366; 2015
  • Recker F, Randazzo M, Wyler SF, Huber A, Cornelius A, Seifert B, Kwiatkowski M. Individuelles risiko-adaptiertes PSA-Screening. Swiss Medical Forum. 15(33):719-722; 2015
  • Randazzo M, Kwiatkowski M, Recker F. PSA-Screening: Nicht «warum» – sondern «wie»! Schweizer Krebsbulletin. (3): 233-35; 2015
  • Recker F, Randazzo M, Kwiatkowski M, Huber A, Burkhardt S. PSA-basiertes Prostatakarzinom-Screening: ein Weg zur Reduktion der «Harms» Seite. Die individuelle Risiko-adaptierte Früherkennung. Info@onkologie. (2):37-39; 2015
  • Kwiatkowski M, Randazzo M, Wyler SF, Recker F. Die ProstateCheck-App im „daily business“ für den Praktiker. Leading Opinions Urologie. (1):20-23; 2015
  • Randazzo M, Kwiatkowski M. Screening des Prostatakarzinoms. How should we do it? Leading Opinions Urologie. (1):20-23; 2015

2014

  • Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Zappa M, Nelen V, Kwiatkowski M, Lujan M, Maattanen L, Lilja H, Denis LJ, Recker F, Paez A, Bangma CH, Carlsson S, Puliti D, Villers A, Rebillard X, Hakama M, Stenman UH, Kujala P, Taari K, Aus G, Huber A, van der Kwast TH, van Schaik RH, de Koning HJ, Moss SM, Auvinen A, Investigators E. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 384(9959):2027-35; 2014
  • Zappa M, Puliti D, Hugosson J, Schroder FH, van Leeuwen PJ, Kranse R, Auvinen A, Carlsson S, Kwiatkowski M, Nelen V, Paez Borda A, Roobol MJ, Villers A. A different method of evaluation of the ERSPC trial confirms that prostate-specific antigen testing has a significant impact on prostate cancer mortality. Eur Urol. 66(3):401-3; 2014
  • Becker A, Seiler D, Kwiatkowski M, Kluth LA, Schnell D, Graefen M, Schlomm T, Fisch M, Recker F, Weissbach L, Chun FK. A comparative assessment of active surveillance for localized prostate cancer in the community versus tertiary care referral center. World Journal of Urology. 32(4):891-7; 2014
  • Kleist C, Randazzo M, Jiga J, Terness P. Heat shock proteins purified from autologous tumors using antibody-based affinity chromatography. Methods Mol Biol. 2014;1139:305-19
  • Randazzo M, Kwiatkowski M, Huber A, Recker F. Der Risiko-adaptierte PSA-Test: Seine neue Rolle als Risikokalkulator im klinischen Alltag. Pipette –Swiss Laboratory medicine. (5):16-17; 2014
  • Wyler SF, Kwiatkowski M, Recker F. Sinnvolle individuelle Vorsorge durch risikoadaptiertes PSA-Screening nach dem Aarauer Modell. Synapse. (5):11-12; 2014

2013

  • Recker F, Seiler D, Seifert B, Randazzo M, Kwiatkowski M. [PSA screening 2013: Background and perspectives.] Urologe A. 2013 May 29
  • Giannarini G, Birkhäuser FD, Recker F, Thalmann GN, Studer UE. Bacillus Calmette-Guérin Failure in Patients with Non-Muscle-invasive Urothelial Carcinoma of the Bladder May Be Due to the Urologist's Failure to Detect Urothelial Carcinoma of the Upper Urinary Tract and Urethra. Eur Urol. 2013 Oct 9
  • Strebel RT, Schmidt C, Beatrice J, Sulser T. Chronic scrotal pain syndrome (CSPS): the widespread use of antibiotics is not justified. Andrology. 2013 Jan;1(1):155-9.
  • Becker A, Placke AK, Kluth LA, Schwarz R, Isbarn H, Chun FK, Heuer R, Schlomm T, Seiler D, Engel O, Fisch M, Graefen M, Ahyai SA. Holmium laser enucleation of the prostate is safe in patients with prostate cancer and lower urinary tract symptoms - a retrospective feasibility study. J Endourol. 2013 Oct 22
  • Kluth LA, Abdollah F, Xylinas E, Rieken M, Fajkovic H, Sun M, Karakiewicz PI, Seitz C, Schramek P, Herman MP, Becker A, Loidl W, Pummer K, Nonis A, Lee RK, Lotan Y, Scherr DS, Seiler D, Chun FK, Graefen M, Tewari A, Gönen M, Montorsi F, Shariat SF, Briganti A. Pathologic Nodal Staging Scores in Patients Treated with Radical Prostatectomy: A Postoperative Decision Tool. Eur Urol. 2013 Jul 2
  • Seiler D, Zheng J, Liu G, Wang S, Yamashiro J, Reiter RE, Huang J, Zeng G. Enrichment of putative prostate cancer stem cells after androgen deprivation: upregulation of pluripotency transactivators concurs with resistance to androgen deprivation in LNCaP cell lines. Prostate. 2013 Sep;73(13):1378-90.
  • Müller A, Bitton A, Vaucher L, Eijsten A, Beatrice J.Erektile Dysfunktion: wie weiter? Praktische Empfehlungen aus Sicht des Urologen. 2013
  • Kwiatkowski M, Huber A. Das PSA im Fokus. Der Informierte Arzt 2013(12);34
  • Horwich A, Hugosson J, de Reijke T, Wiegel T, Fizazi K, Kataja V & Panel Members. Prostate cancer: ESMO Consensus Conference Guidelines 2012. Annals of Oncology 2013;1-22

2012

  • Olkhov-Mitsel E, Van der Kwast T, Kron KJ, Ozcelik H, Briollais L, Massey C, Recker F, Kwiatkowski M, Fleshner NE, Diamandis EP, Zlotta AR, Bapat B. Quantitative DNA methylation analysis of genes coding for kallikrein-related peptidases 6 and 10 as biomarkers for prostate cancer. Epigenetics. 2012 Sep;7(9):1037-45
  • Horwich A, Hugosson J, de Reijke T, Wiegel T, Fizazi K, Kataja V & Panel Members. Prostate cancer: ESMO Consensus Conference Guidelines 2012. Annals of Oncology 2013;1-22
  • Schröder FH, Hugosson J, Carlsson S, Tammela T, Määttänen L, Auvinen A, Kwiatkowski M, Recker F, Roobol MJ. Screening for Prostate Cancer Decreases the Risk of Developing Metastatic Disease: Findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC). Eur Urol. 2012;62:745-52
  • Heijnsdijk EA, Wever EM, Auvinen A, Hugosson J, Ciatto S, Nelen V, Kwiatkowski M, Villers A, Páez A, Moss SM, Zappa M, Tammela TL, Mäkinen T, Carlsson S, Korfage IJ, Essink-Bot ML, Otto SJ, Draisma G, Bangma CH, Roobol MJ, Schröder FH, de Koning HJ. Quality-of-life effects of prostate-specific antigen screening. N Engl J Med. 2012 Aug 16;367(7):595-605.
  • Randazzo M, Kwiatkowski M, Recker F. PSA und Prostatakrebsfrüherkennung. Schweizerische Zeitschrift für Onkologie 3/ 2012.
  • Seiler D, Randazzo M, Klotz L, Grobholz R, Baumgartner M, Isbarn H, Recker F and Kwiatkowski M. Pathological stage distribution in patients treated with radical prostatectomy reflecting the need for protocol-based active surveillance: results from a contemporary European patient cohort. BJU Int. 2012;110:195-200
  • Randazzo M, Terness P, Opelz G, Kleist C. Active specific immunotherapy of human cancers with the heat shock protein Gp96 –revisited. Int J Cancer. 2012 May 15;130(10):2219-31
  • Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Páez A, Määttänen L, Bangma CH, Aus G, Carlsson S, Villers A, Rebillard X, van der Kwast T, Kujala PM, Blijenberg BG, Stenman UH, Huber A, Taari K, Hakama M, Moss SM, de Koning HJ and Auvinen A. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med. 2012 Mar 15;366(11):981-90
  • Seiler D, Randazzo M, Leupold U, Zeh N, Isbarn H, Chun FK, Ahyai SA, Baumgartner M, Huber A, Recker F, Kwiatkowski M. Protocol-based Active Surveillance for Low-risk Prostate Cancer: Anxiety Levels in Both Men and Their Partners. Urology. 2012 Sep;80(3):564-9
  • Kwiatkowski M, Klotz L, Hugosson J, Recker F. Comment on the US Preventive Services Task Force's Draft Recommendation on Screening for Prostate Cancer. Eur Urol. 2012;61:851-4
  • Randazzo M, Recker F. Feinere Filter – bessere Behandlung. VSAO Journal 2012, April; 2: 40-43
  • Recker F. „U.S. Preventive Services Task Force Recommendation“ oder „Das Kind mit dem Bade ausschütten“. Urologe 2012;51:74-76

2011

  • Cathomas R, Berthold D, Gillessen S, Recker F, Stenner F, Strebel R, Sulser T, Zwahlen DR, Schmid H-P. Das Prostatakarzinom im Wandel; Grundpfeiler der Diagnostik, Behandlung und Interdisziplinarität. Schweiz Med Forum 2011;11(43):759-763
  • Recker F, Sulser T. Messung des prostataspezifischen Antigens (PSA-Test) zur Früherkennung des Prostatakarzinoms; Swiss Medical Board oder: "Das Kind mit dem Bade ausschütten". Schweizerische Ärztezeitung 2011; 92:51/52
  • Randazzo M, Seiler D, Recker F, Kwiatkowski M. PSA-Screening in der Prostatakarzinomvorsorge – Versuch einer kritischen Analyse. Hausarzt Praxis 2011 September; 11-14

2010

  • Möltgen T, Gräfe K, Seiler D, Recker F, Kwiatkowski M. Prostata-Karzinom-Screening: Wo stehen wir nach den Kontroversen? Hausarzt Praxis 2/10
  • Kwiatkowski M, Recker F, Huber A, Sergeeva NA, Brinkmann T. Standardization of the laboratory test for PSA. Urologiia 2010;(4):64, 66-7
  • Boevee SJ, Venderbos LD, Tammela TL, Nelen V, Ciatto S, Kwiatkowski M, Paez A, Malavaud B, Hugosson J, Roobol MJ. Change of tumour characteristics and treatment over time in both arms of the European Randomized study of Screening for Prostate Cancer. Eur J Cancer 2010;46:3082-9
  • Otto SJ, Moss SM, Maattanen L, Roobol M, Zappa M, Nelen V, Kwiatkowski M, Villers A, Hugosson J, Sanchez AB, de Koning HJ. PSA levels and cancer detection rate by centre in the European Randomized Study of Screening for Prostate Cancer. Eur J Cancer 2010;46:3053-60
  • Recker F. Vertiefte Analyse zweier Studien zum Prostatakarzinom-Screening – Was macht Sinn? Praxis 2010;99: 183-185

2009

  • Wolters T, Roobol MJ, Steyerberg EW, van den Bergh RC, Bangma CH, Hugosson J, Ciatto S, Kwiatkowski M, Villers A, Lujan M, Nelen V, Tammela TL, Schroder FH. The effect of study arm on prostate cancer treatment in the large screening trial ERSPC. International Journal of Cancer 2009;126:2387-93
  • Roobol MJ, Kerkhof M, Schroder FH, Cuzick J, Sasieni P, Hakama M, Stenman UH, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis L, Recker F, Berenguer A, Ruutu M, Kujala P, Bangma CH, Aus G, Tammela TL, Villers A, Rebillard X, Moss SM, de Koning HJ, Hugosson J, Auvinen A. Prostate Cancer Mortality Reduction by Prostate-Specific Antigen-Based Screening Adjusted for Nonattendance and Contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC). European Urology 2009;56:584-91
  • Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Maattanen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A. Screening and prostate-cancer mortality in a randomized European study. The New England Journal of Medicine 2009;360:1320-8

2008

  • Kwiatkowski M, Stieber P, Huber AR, Recker F. [Selective application of tumor markers PSA]. Therapeutische Umschau. 2008;65:493-501
  • Arndt B, Kwiatkowski M, Recker F. [Status of care for prostate cancer in 2008]. Der Urologe 2008;47:969-74

2006

  • Stephan C, Meyer HA, Kwiatkowski M, Recker F, Cammann H, Loening SA, Jung K, Lein M. A (-5, -7) proPSA based artificial neural network to detect prostate cancer. Eur Urol 2006;50:1014-20
  • Recker F. Prostate specific antigen in individual cancer checkups and in therapeutic treatment. Ther Umsch 2006;63:135-41

2005

  • Lein M, Semjonow A, Graefen M, Kwiatkowski M, Abramjuk C, Stephan C, Haese A, Chun F, Schnorr D, Loening SA, Jung K. A multicenter clinical trial on the use of (-5, -7) pro PSA. J Urol. 2005;174:2150-2153
  • Recker F. Wann ist eine PSA-Bestimmung sinnvoll? Primary Care 2005;5:328-329
  • Keller T, Butz H, Lein M, Kwiatkowski M, Semjonow A, Luboldt HJ, Hammerer P, Stephan C, Jung K. Discordance analysis characteristics as a new method to compare the diagnostic accuracy of tests: example of complexed versus total prostate-specific antigen. Clin Chem. 2005;51:532-9

2004

  • Kwiatkowski M, Huber A, Moschopulos M, Lehmann K, Wernli M, Häfeli A, Recker F. Screening for prostate cancer. Results of a prospective trial in Canton Aargau, Switzerland. Swiss Med Wkly 2004;134:580–585
  • Recker F, Kwiatkowski M. PSA-Screening for prostate cancer - yes or no? Ther Umschau 2004;61:353-8
  • Recker F, Kwiatkowski M. Prostatakrebs: Wo steht die Vorsorge im Jahr 2004? Schweiz Med Forum 2004;4:509–512

2003

  • Heiss P, Kwiatkowski M, Lenz H, Pettersson K, Recker F, Hösel W, Eckert B. Human glandular kallikrein 2 and [-7]proPSA can improve the specificity of prostate cancer within PSA range 2-4 ng/ml. Anticancer Research, 23 (6B): V1, 2003
  • Zusammenarbeit bei der Herausgabe des Supplements: The European Randomised Study of Screening for Prostate Cancer (ERSPC): rationale, structure and preliminary results 1994-2003. BJU Int. 2003, 92 (Suppl.2).
  • Schroder FH, Denis LJ, Roobol M, Nelen V, Auvinen A, Tammela T, Villers A, Rebillard X, Ciatto S, Zappa M, Berenguer A, Paez A, Hugosson J, Lodding P, Recker F, Kwiatkowski M, Kirkels WJ; ERSPC. The story of the European Randomized Study of Screening for Prostate Cancer. BJU Int. 2003 Dec;92 Suppl 2:1-13.
  • Kwiatkowski M, Huber A, Stamm B, Lehmann K, Wernli M, Häfeli A, Recker F. Features and preliminary results of prostate cancer screening in Canton Aargau, Switzerland. BJU Int. 2003;92 (Suppl.2):44-47
  • Lein M, Kwiatkowski M, Semjonow A, Luboldt H-J, Hammerer P, Stephan C, Klevecka V, Taymoorian K, Schnorr D, Recker F, Loening S, Jung K: A multicenter clinical trial on the use of complexed prostate specific antigen in low prostate specific antigen concentrations. J Urol 2003;170:1175-1179

2001

  • Recker F, Kwiatkowski MK, Huber A, Stamm B, Lehmann K, Tscholl R. Prospective detection of clinically relevant prostate cancer in the prostate specific antigen range 1 to 3 ng./ml. combined with free-to-total ratio 20% or less: the Aarau experience. J Urol 166:851-5, 2001
  • Recker F. Vorsorgeuntersuchung und diagnostischer Algorithmus. In: Prostatakrebs. Fakten und Handlungsbedarf. Nationales Krebs-Bekämpfungsprogramm, S. 24-26. Hrsg. Bundesamt für Gesundheit und Krebsliga Schweiz.

2000

  • Recker F, Lummen G: Prostatic carcinoma. Screening--when and what?. Ther Umsch 57: 33-7, 2000
  • Recker F, Kwiatkowski M, Piironen T, Pettersson K, Huber A, Lummen G, Tscholl R. Human glandular kallikrein as a tool to improve discrimination of poorly differentiated and non-organ-confined prostate cancer compared with prostate-specific antigen. Urology 55: 481-5, 2000

1999

  • Recker F, Kwiatkowski M, Piironen T, Otto T, Tscholl R. Korrelationen von human glandulärem Kallikrein mit freiem, total und an alpha 1 Antichymotrypsin gebundenem PSA bei unterschiedlichen Prostataerkrankungen 160-164. In: Urologie im Wandel Hrsg.Jonas 1999, Biermann Verlag,160-164

1998

  • Recker F, Kwiatkowski M.K, Piironen T, Pettersson K, Lummen G, Wernli M, Wiefelsputz J, Graber S.F, Huber A, Tscholl R. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma. Cancer 1998;83:2540-2547
  • Kwiatkowski M.K, Recker F, Piironen T, Pettersson K, Otto T, Wernli M, Tscholl R. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic ”gray zone” of total PSA 4 to 10 ng/ml. Urology 1998;52:360-365
  • Recker F, Kwiatkowski M.K, Piironen T. Improving the specificity of PSA's in the diagnostic gray zone 4-10 ng/ml by human glandular kallikrein. Urologe A 1998;37:421-423
  • Recker F, Kwiatkowski M.K, Piironen T, Pettersson K, Goepel M, Tscholl R. Free-to-total prostate-specific antigen (PSA) ratio improves the specificity for detecting prostate cancer in patients with prostatism and intermediate PSA levels. Br J Urol 81:532, 1998
  • Recker F, Kwiatkowski M.K, Pettersson K, Piironen T, Lummen G, Huber A, Tscholl R. Enhanced expression of prostate-specific antigen in the transition zone of the prostate. A characterization following prostatectomy for benign hyperplasia. Eur Urol 1998;33:549-55

1997

  • Recker F, Kwiatkowski M, Pettersson K, Piironen T, Reisto T, Tscholl R. Serum expression of different prostate specific antigen forms in different zones of the prostate. Urological Research 25:96, 1997

1996

  • Recker F. What influence has the introduction of the prostate-specific antigen on the diagnostic of organ-confined prostate cancer. Urologe B, 1996;36:266
  • Recker F. Prostate-specific antigen in the diagnosis of organ-confined treatable prostate carcinoma. Schweiz Med Wochenschr 1996;126:1881

© 2018 | Prostatazentrum Kantonsspital Aarau | Impressum | Disclamer | Intern Login

top